Definitive Contract INN10PC20116

This is a $5,632,809.00 Cost Plus Fixed Fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Leidos, Inc. (Leidos) to develop technologies that enable immediate synthesis of bioactive protein medical countermeasures and production enzymes within 24 hours at a yield of at least 500 doses per week. The contract is part of DARPA's Reimagining Protein Manufacturing (RPM) program, which aims to establish foundational technologies for distributed, on-demand manufacturing of...

This is a $225,000.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Technology Holding LLC, a small, for-profit limited liability company specializing in research and development services. The contract is part of DARPA's Small Business Innovation Research (SBIR) program and is for Phase I of an effort titled "AUTONOMOUS BIOMANUFACTORING AT REMOTE LOCATIONS". The contract has a total small business set-aside and supports the development of...

This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...

This is a $3,247,731 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of a first-in-human therapeutic interfering particle targeting a respiratory virus, under DARPA's research programs. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) by DARPA, with a potential value of $4,579,822, to develop and deliver therapeutic...

The U.S. Defense Health Agency (DHA) awarded a $1,303,426.92 firm fixed price purchase order to Eitr Biologics, Inc., a small business biotechnology company, to sort peripheral blood mononuclear cells from Lassa fever virus survivors and discover and produce monoclonal antibodies for assessment in in-vitro and in-vivo assays. This award is part of Eitr Biologics' Indefinite Delivery Vehicle (IDV) contract with the DHA, valued at $4.39 million, for developing novel nanotherapeutics to combat...

This is a $749,986 firm-fixed-price federal contract awarded to Design-Zyme LLC, a small biotechnology company, by the Defense Advanced Research Projects Agency (DARPA). The contract is for a study on "Enhanced Enzymes for Long-Term Continuous Monitoring Applications" under DARPA's Biological Technologies Office (BTO). The contract has a completion date of December 31, 2017 and does not utilize a set-aside. Based on Design-Zyme LLC's background, the contract likely involves the...

This federal contract award was issued by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, to Renbio, Inc., a for-profit biotechnology company. The $749,289.42 firm-fixed-price definitive contract, awarded on April 29, 2024, is for research and development on DNA-based delivery of anti-influenza antibodies to large animals under AOI#25 (FASTX) for myo technology. The contract, which has a completion date of February 27, 2026,...

This is a $11,295.00 firm fixed price purchase order awarded to Research And Diagnostic Systems, Inc. (R&D Systems) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract is for the provision of recombinant human proteins and antibodies, which are essential research reagents used in studies of infectious diseases, cancer, and other health conditions. R&D Systems is a subsidiary of the parent...

This is a $546,696 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to the University of California, San Diego (UCSD) to develop engineered bacterial spores as "sleeper agents" to infiltrate and activate within emerging biofilms. The contract has no set-aside designation. UCSD, as a premier public research university, has a long history of supporting DARPA and other federal agencies through a diverse portfolio of research contracts and grants. This...

This is a $7,994,572.00 cost-plus-fixed-fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence (MOD), doing business as the Defence Science and Technology Laboratory (DSTL), a United Kingdom government entity. The contract is for the generation of a novel antibody-antibiotic conjugate as a combination therapy platform to treat melioidosis or plague. This contract is not set aside. DSTL has secured multiple high-value federal contracts from DTRA...